• In April 2026, Indivior PLC reported results from a national survey showing that correctional leaders see staffing and coordination gaps as major barriers to preventing diversion of medications for opioid use disorder, and view long-acting injectable buprenorphine as a practical way to improve treatment in jails and prisons.
• The survey’s strong support among correctional professionals for long-acting injectable buprenorphine highlights a potential opportunity for wider use of Indivior’s treatment within the criminal justice system.
• We’ll now examine how this emerging support for long-acting injectable buprenorphine in correctional settings could influence Indivior’s broader investment narrative.

Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

Indivior Pharmaceuticals Investment Narrative Recap

To own Indivior, you need to believe that long acting injectable treatments can become a central option in opioid use disorder care, with SUBLOCADE at the core. The new survey support from correctional leaders reinforces the idea that jails and prisons could become a meaningful channel, but it does not obviously change the key near term catalyst, which remains execution on SUBLOCADE growth, or the main risk, which is that long acting injectables fail to gain broader adoption.

The most relevant recent announcement here is Indivior’s March 2026 cost impact model for SUBLOCADE in correctional settings, which suggested lower staff time and certain operational costs compared with other medications for opioid use disorder. Together with the April survey, this builds a more coherent story for SUBLOCADE in the criminal justice system, potentially supporting the broader catalysts of growing long acting injectable use and improved operating leverage if correctional demand translates into sustained volumes.

Yet investors should also weigh how reliance on long acting injectables in a still underpenetrated market could become a vulnerability if...

Indivior Pharmaceuticals' narrative projects $1.2 billion revenue and $477.5 million earnings by 2028. This requires 1.7% yearly revenue growth and a $353.5 million earnings increase from $124.0 million today.

Uncover how Indivior Pharmaceuticals' forecasts yield a $37.86 fair value, a 16% upside to its current price.

Exploring Other Perspectives

Before this survey, the most optimistic analysts were already assuming revenue could reach about US$1.3 billion and earnings roughly US$596 million by 2029, so if correctional uptake accelerates long acting injectable adoption, that bullish view could gain support, while the contrasting risk that adoption stalls well below other chronic categories reminds you that opinions differ and both narratives may shift as new data emerges.

Explore 4 other fair value estimates on Indivior Pharmaceuticals - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Indivior Pharmaceuticals research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Indivior Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Indivior Pharmaceuticals' overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.
• Find 60 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.